HealthCare Global Enterprises Limited
HealthCare Global Enterprises Limited (HCG.BO) Stock Competitors & Peer Comparison
See (HCG.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCG.BO | ₹634.95 | -2.59% | 93.6B | 639.80 | ₹0.98 | N/A |
| APOLLOHOSP.NS | ₹8,320.00 | +2.99% | 1.2T | 61.59 | ₹134.91 | +0.24% |
| APOLLOHOSP.BO | ₹8,329.00 | +2.84% | 1.2T | 61.64 | ₹134.71 | +0.24% |
| MAXHEALTH.BO | ₹1,017.00 | -5.51% | 1.1T | 75.12 | ₹14.53 | +0.14% |
| MAXHEALTH.NS | ₹1,023.95 | -4.81% | 1.1T | 75.14 | ₹14.52 | +0.14% |
| FORTIS.NS | ₹953.35 | -2.18% | 730.3B | 75.75 | ₹12.77 | +0.10% |
| FORTIS.BO | ₹953.10 | -2.15% | 730.1B | 76.27 | ₹12.68 | +0.10% |
| ASTERDM.NS | ₹765.35 | +0.07% | 392.5B | 119.19 | ₹6.37 | +0.53% |
| NH.NS | ₹1,889.00 | -0.70% | 392.2B | 50.49 | ₹38.24 | +0.23% |
| ASTERDM.BO | ₹762.60 | -0.21% | 392B | 117.76 | ₹6.44 | +0.53% |
Stock Comparison
HCG.BO vs APOLLOHOSP.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, APOLLOHOSP.NS has a market cap of 1.2T. Regarding current trading prices, HCG.BO is priced at ₹634.95, while APOLLOHOSP.NS trades at ₹8,320.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas APOLLOHOSP.NS's P/E ratio is 61.59. In terms of profitability, HCG.BO's ROE is +0.01%, compared to APOLLOHOSP.NS's ROE of +0.22%. Regarding short-term risk, HCG.BO is less volatile compared to APOLLOHOSP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check APOLLOHOSP.NS's competition here
HCG.BO vs APOLLOHOSP.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, APOLLOHOSP.BO has a market cap of 1.2T. Regarding current trading prices, HCG.BO is priced at ₹634.95, while APOLLOHOSP.BO trades at ₹8,329.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas APOLLOHOSP.BO's P/E ratio is 61.64. In terms of profitability, HCG.BO's ROE is +0.01%, compared to APOLLOHOSP.BO's ROE of +0.22%. Regarding short-term risk, HCG.BO is less volatile compared to APOLLOHOSP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check APOLLOHOSP.BO's competition here
HCG.BO vs MAXHEALTH.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, MAXHEALTH.BO has a market cap of 1.1T. Regarding current trading prices, HCG.BO is priced at ₹634.95, while MAXHEALTH.BO trades at ₹1,017.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas MAXHEALTH.BO's P/E ratio is 75.12. In terms of profitability, HCG.BO's ROE is +0.01%, compared to MAXHEALTH.BO's ROE of +0.15%. Regarding short-term risk, HCG.BO is less volatile compared to MAXHEALTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MAXHEALTH.BO's competition here
HCG.BO vs MAXHEALTH.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, MAXHEALTH.NS has a market cap of 1.1T. Regarding current trading prices, HCG.BO is priced at ₹634.95, while MAXHEALTH.NS trades at ₹1,023.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas MAXHEALTH.NS's P/E ratio is 75.14. In terms of profitability, HCG.BO's ROE is +0.01%, compared to MAXHEALTH.NS's ROE of +0.15%. Regarding short-term risk, HCG.BO is less volatile compared to MAXHEALTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MAXHEALTH.NS's competition here
HCG.BO vs FORTIS.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, FORTIS.NS has a market cap of 730.3B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while FORTIS.NS trades at ₹953.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas FORTIS.NS's P/E ratio is 75.75. In terms of profitability, HCG.BO's ROE is +0.01%, compared to FORTIS.NS's ROE of +0.11%. Regarding short-term risk, HCG.BO is less volatile compared to FORTIS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check FORTIS.NS's competition here
HCG.BO vs FORTIS.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, FORTIS.BO has a market cap of 730.1B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while FORTIS.BO trades at ₹953.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas FORTIS.BO's P/E ratio is 76.27. In terms of profitability, HCG.BO's ROE is +0.01%, compared to FORTIS.BO's ROE of +0.11%. Regarding short-term risk, HCG.BO is less volatile compared to FORTIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check FORTIS.BO's competition here
HCG.BO vs ASTERDM.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, ASTERDM.NS has a market cap of 392.5B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while ASTERDM.NS trades at ₹765.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas ASTERDM.NS's P/E ratio is 119.19. In terms of profitability, HCG.BO's ROE is +0.01%, compared to ASTERDM.NS's ROE of +0.10%. Regarding short-term risk, HCG.BO is less volatile compared to ASTERDM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check ASTERDM.NS's competition here
HCG.BO vs NH.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, NH.NS has a market cap of 392.2B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while NH.NS trades at ₹1,889.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas NH.NS's P/E ratio is 50.49. In terms of profitability, HCG.BO's ROE is +0.01%, compared to NH.NS's ROE of +0.21%. Regarding short-term risk, HCG.BO is less volatile compared to NH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check NH.NS's competition here
HCG.BO vs ASTERDM.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, ASTERDM.BO has a market cap of 392B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while ASTERDM.BO trades at ₹762.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas ASTERDM.BO's P/E ratio is 117.76. In terms of profitability, HCG.BO's ROE is +0.01%, compared to ASTERDM.BO's ROE of +0.10%. Regarding short-term risk, HCG.BO is less volatile compared to ASTERDM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check ASTERDM.BO's competition here
HCG.BO vs NH.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, NH.BO has a market cap of 391.7B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while NH.BO trades at ₹1,886.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas NH.BO's P/E ratio is 46.41. In terms of profitability, HCG.BO's ROE is +0.01%, compared to NH.BO's ROE of +0.21%. Regarding short-term risk, HCG.BO is less volatile compared to NH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check NH.BO's competition here
HCG.BO vs MEDANTA.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, MEDANTA.NS has a market cap of 333.4B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while MEDANTA.NS trades at ₹1,235.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas MEDANTA.NS's P/E ratio is 59.88. In terms of profitability, HCG.BO's ROE is +0.01%, compared to MEDANTA.NS's ROE of +0.15%. Regarding short-term risk, HCG.BO is less volatile compared to MEDANTA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MEDANTA.NS's competition here
HCG.BO vs MEDANTA.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, MEDANTA.BO has a market cap of 333.1B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while MEDANTA.BO trades at ₹1,241.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas MEDANTA.BO's P/E ratio is 59.98. In terms of profitability, HCG.BO's ROE is +0.01%, compared to MEDANTA.BO's ROE of +0.15%. Regarding short-term risk, HCG.BO is less volatile compared to MEDANTA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MEDANTA.BO's competition here
HCG.BO vs KIMS.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, KIMS.BO has a market cap of 308B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while KIMS.BO trades at ₹766.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas KIMS.BO's P/E ratio is 128.30. In terms of profitability, HCG.BO's ROE is +0.01%, compared to KIMS.BO's ROE of +0.11%. Regarding short-term risk, HCG.BO is less volatile compared to KIMS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check KIMS.BO's competition here
HCG.BO vs KIMS.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, KIMS.NS has a market cap of 307.8B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while KIMS.NS trades at ₹767.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas KIMS.NS's P/E ratio is 128.19. In terms of profitability, HCG.BO's ROE is +0.01%, compared to KIMS.NS's ROE of +0.11%. Regarding short-term risk, HCG.BO is less volatile compared to KIMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check KIMS.NS's competition here
HCG.BO vs RAINBOW.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, RAINBOW.BO has a market cap of 136.6B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while RAINBOW.BO trades at ₹1,341.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas RAINBOW.BO's P/E ratio is 53.22. In terms of profitability, HCG.BO's ROE is +0.01%, compared to RAINBOW.BO's ROE of +0.18%. Regarding short-term risk, HCG.BO is less volatile compared to RAINBOW.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check RAINBOW.BO's competition here
HCG.BO vs RAINBOW.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, RAINBOW.NS has a market cap of 136.6B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while RAINBOW.NS trades at ₹1,342.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas RAINBOW.NS's P/E ratio is 53.22. In terms of profitability, HCG.BO's ROE is +0.01%, compared to RAINBOW.NS's ROE of +0.18%. Regarding short-term risk, HCG.BO is less volatile compared to RAINBOW.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check RAINBOW.NS's competition here
HCG.BO vs HCG.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, HCG.NS has a market cap of 93.6B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while HCG.NS trades at ₹637.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas HCG.NS's P/E ratio is 639.80. In terms of profitability, HCG.BO's ROE is +0.01%, compared to HCG.NS's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to HCG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check HCG.NS's competition here
HCG.BO vs JLHL.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, JLHL.BO has a market cap of 86.1B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while JLHL.BO trades at ₹1,328.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas JLHL.BO's P/E ratio is 44.50. In terms of profitability, HCG.BO's ROE is +0.01%, compared to JLHL.BO's ROE of +0.14%. Regarding short-term risk, HCG.BO is less volatile compared to JLHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check JLHL.BO's competition here
HCG.BO vs JLHL.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, JLHL.NS has a market cap of 86B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while JLHL.NS trades at ₹1,323.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas JLHL.NS's P/E ratio is 44.47. In terms of profitability, HCG.BO's ROE is +0.01%, compared to JLHL.NS's ROE of +0.14%. Regarding short-term risk, HCG.BO is less volatile compared to JLHL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check JLHL.NS's competition here
HCG.BO vs YATHARTH.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, YATHARTH.NS has a market cap of 82.8B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while YATHARTH.NS trades at ₹854.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas YATHARTH.NS's P/E ratio is 49.39. In terms of profitability, HCG.BO's ROE is +0.01%, compared to YATHARTH.NS's ROE of +0.11%. Regarding short-term risk, HCG.BO is less volatile compared to YATHARTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check YATHARTH.NS's competition here
HCG.BO vs YATHARTH.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, YATHARTH.BO has a market cap of 82.8B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while YATHARTH.BO trades at ₹854.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas YATHARTH.BO's P/E ratio is 49.43. In terms of profitability, HCG.BO's ROE is +0.01%, compared to YATHARTH.BO's ROE of +0.11%. Regarding short-term risk, HCG.BO is less volatile compared to YATHARTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check YATHARTH.BO's competition here
HCG.BO vs KOVAI.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, KOVAI.NS has a market cap of 73.8B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while KOVAI.NS trades at ₹5,365.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas KOVAI.NS's P/E ratio is 25.07. In terms of profitability, HCG.BO's ROE is +0.01%, compared to KOVAI.NS's ROE of +0.22%. Regarding short-term risk, HCG.BO is more volatile compared to KOVAI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check KOVAI.NS's competition here
HCG.BO vs KOVAI.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, KOVAI.BO has a market cap of 59.1B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while KOVAI.BO trades at ₹5,398.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas KOVAI.BO's P/E ratio is 25.07. In terms of profitability, HCG.BO's ROE is +0.01%, compared to KOVAI.BO's ROE of +0.22%. Regarding short-term risk, HCG.BO is more volatile compared to KOVAI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check KOVAI.BO's competition here
HCG.BO vs ARTEMISMED.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, ARTEMISMED.BO has a market cap of 44.3B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while ARTEMISMED.BO trades at ₹275.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas ARTEMISMED.BO's P/E ratio is N/A. In terms of profitability, HCG.BO's ROE is +0.01%, compared to ARTEMISMED.BO's ROE of +0.12%. Regarding short-term risk, HCG.BO is less volatile compared to ARTEMISMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check ARTEMISMED.BO's competition here
HCG.BO vs ARTEMISMED.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, ARTEMISMED.NS has a market cap of 44.1B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while ARTEMISMED.NS trades at ₹274.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas ARTEMISMED.NS's P/E ratio is 121.97. In terms of profitability, HCG.BO's ROE is +0.01%, compared to ARTEMISMED.NS's ROE of +0.12%. Regarding short-term risk, HCG.BO is less volatile compared to ARTEMISMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check ARTEMISMED.NS's competition here
HCG.BO vs INDRAMEDCO.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, INDRAMEDCO.BO has a market cap of 32.6B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while INDRAMEDCO.BO trades at ₹356.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas INDRAMEDCO.BO's P/E ratio is 17.76. In terms of profitability, HCG.BO's ROE is +0.01%, compared to INDRAMEDCO.BO's ROE of +0.28%. Regarding short-term risk, HCG.BO is less volatile compared to INDRAMEDCO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check INDRAMEDCO.BO's competition here
HCG.BO vs INDRAMEDCO.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, INDRAMEDCO.NS has a market cap of 32.6B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while INDRAMEDCO.NS trades at ₹356.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas INDRAMEDCO.NS's P/E ratio is 17.74. In terms of profitability, HCG.BO's ROE is +0.01%, compared to INDRAMEDCO.NS's ROE of +0.28%. Regarding short-term risk, HCG.BO is less volatile compared to INDRAMEDCO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check INDRAMEDCO.NS's competition here
HCG.BO vs DRAGARWQ.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, DRAGARWQ.BO has a market cap of 24.6B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while DRAGARWQ.BO trades at ₹5,087.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas DRAGARWQ.BO's P/E ratio is 34.44. In terms of profitability, HCG.BO's ROE is +0.01%, compared to DRAGARWQ.BO's ROE of +0.30%. Regarding short-term risk, HCG.BO is less volatile compared to DRAGARWQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check DRAGARWQ.BO's competition here
HCG.BO vs SHALBY.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, SHALBY.BO has a market cap of 18.3B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while SHALBY.BO trades at ₹170.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas SHALBY.BO's P/E ratio is 218.78. In terms of profitability, HCG.BO's ROE is +0.01%, compared to SHALBY.BO's ROE of +0.01%. Regarding short-term risk, HCG.BO is more volatile compared to SHALBY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check SHALBY.BO's competition here
HCG.BO vs SHALBY.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, SHALBY.NS has a market cap of 18.3B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while SHALBY.NS trades at ₹170.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas SHALBY.NS's P/E ratio is 221.42. In terms of profitability, HCG.BO's ROE is +0.01%, compared to SHALBY.NS's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to SHALBY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check SHALBY.NS's competition here
HCG.BO vs KMCSHIL.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, KMCSHIL.BO has a market cap of 15.4B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while KMCSHIL.BO trades at ₹95.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas KMCSHIL.BO's P/E ratio is 42.23. In terms of profitability, HCG.BO's ROE is +0.01%, compared to KMCSHIL.BO's ROE of +0.21%. Regarding short-term risk, HCG.BO is less volatile compared to KMCSHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check KMCSHIL.BO's competition here
HCG.BO vs GPTHEALTH.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, GPTHEALTH.NS has a market cap of 11.5B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while GPTHEALTH.NS trades at ₹138.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas GPTHEALTH.NS's P/E ratio is 28.47. In terms of profitability, HCG.BO's ROE is +0.01%, compared to GPTHEALTH.NS's ROE of +0.17%. Regarding short-term risk, HCG.BO is less volatile compared to GPTHEALTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check GPTHEALTH.NS's competition here
HCG.BO vs MAXINDIA.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, MAXINDIA.BO has a market cap of 9.2B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while MAXINDIA.BO trades at ₹213.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas MAXINDIA.BO's P/E ratio is -3560.83. In terms of profitability, HCG.BO's ROE is +0.01%, compared to MAXINDIA.BO's ROE of +0.15%. Regarding short-term risk, HCG.BO is less volatile compared to MAXINDIA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MAXINDIA.BO's competition here
HCG.BO vs MAXIND.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, MAXIND.NS has a market cap of 8.3B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while MAXIND.NS trades at ₹158.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas MAXIND.NS's P/E ratio is -5.30. In terms of profitability, HCG.BO's ROE is +0.01%, compared to MAXIND.NS's ROE of -0.36%. Regarding short-term risk, HCG.BO is less volatile compared to MAXIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MAXIND.NS's competition here
HCG.BO vs UNIHEALTH.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, UNIHEALTH.NS has a market cap of 7.2B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while UNIHEALTH.NS trades at ₹452.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas UNIHEALTH.NS's P/E ratio is 46.06. In terms of profitability, HCG.BO's ROE is +0.01%, compared to UNIHEALTH.NS's ROE of N/A. Regarding short-term risk, HCG.BO is less volatile compared to UNIHEALTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check UNIHEALTH.NS's competition here
HCG.BO vs ASARFI.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, ASARFI.BO has a market cap of 3.8B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while ASARFI.BO trades at ₹194.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas ASARFI.BO's P/E ratio is 23.43. In terms of profitability, HCG.BO's ROE is +0.01%, compared to ASARFI.BO's ROE of +0.13%. Regarding short-term risk, HCG.BO is less volatile compared to ASARFI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check ASARFI.BO's competition here
HCG.BO vs LOTUSEYE.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, LOTUSEYE.NS has a market cap of 2.2B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while LOTUSEYE.NS trades at ₹107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas LOTUSEYE.NS's P/E ratio is 336.97. In terms of profitability, HCG.BO's ROE is +0.01%, compared to LOTUSEYE.NS's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to LOTUSEYE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check LOTUSEYE.NS's competition here
HCG.BO vs LOTUSEYE.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, LOTUSEYE.BO has a market cap of 2.2B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while LOTUSEYE.BO trades at ₹105.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas LOTUSEYE.BO's P/E ratio is 330.31. In terms of profitability, HCG.BO's ROE is +0.01%, compared to LOTUSEYE.BO's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to LOTUSEYE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check LOTUSEYE.BO's competition here
HCG.BO vs MADHAVBAUG.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, MADHAVBAUG.NS has a market cap of 2B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while MADHAVBAUG.NS trades at ₹193.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas MADHAVBAUG.NS's P/E ratio is 25.02. In terms of profitability, HCG.BO's ROE is +0.01%, compared to MADHAVBAUG.NS's ROE of N/A. Regarding short-term risk, HCG.BO is less volatile compared to MADHAVBAUG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MADHAVBAUG.NS's competition here
HCG.BO vs LEHIL.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, LEHIL.BO has a market cap of 1.9B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while LEHIL.BO trades at ₹89.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas LEHIL.BO's P/E ratio is -315.00. In terms of profitability, HCG.BO's ROE is +0.01%, compared to LEHIL.BO's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to LEHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check LEHIL.BO's competition here
HCG.BO vs AASHKA.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, AASHKA.BO has a market cap of 1.8B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while AASHKA.BO trades at ₹75.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas AASHKA.BO's P/E ratio is 72.12. In terms of profitability, HCG.BO's ROE is +0.01%, compared to AASHKA.BO's ROE of +0.02%. Regarding short-term risk, HCG.BO is more volatile compared to AASHKA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check AASHKA.BO's competition here
HCG.BO vs JSTL.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, JSTL.BO has a market cap of 1.3B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while JSTL.BO trades at ₹82.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas JSTL.BO's P/E ratio is -64.36. In terms of profitability, HCG.BO's ROE is +0.01%, compared to JSTL.BO's ROE of -0.06%. Regarding short-term risk, HCG.BO is less volatile compared to JSTL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check JSTL.BO's competition here
HCG.BO vs ASPIRA.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, ASPIRA.BO has a market cap of 1.1B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while ASPIRA.BO trades at ₹112.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas ASPIRA.BO's P/E ratio is 78.45. In terms of profitability, HCG.BO's ROE is +0.01%, compared to ASPIRA.BO's ROE of +0.11%. Regarding short-term risk, HCG.BO is less volatile compared to ASPIRA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check ASPIRA.BO's competition here
HCG.BO vs FORTISMLR.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, FORTISMLR.BO has a market cap of 1B. Regarding current trading prices, HCG.BO is priced at ₹634.95, while FORTISMLR.BO trades at ₹54.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas FORTISMLR.BO's P/E ratio is 22.12. In terms of profitability, HCG.BO's ROE is +0.01%, compared to FORTISMLR.BO's ROE of +0.13%. Regarding short-term risk, HCG.BO is less volatile compared to FORTISMLR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check FORTISMLR.BO's competition here
HCG.BO vs MAITREYA.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, MAITREYA.NS has a market cap of 934M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while MAITREYA.NS trades at ₹172.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas MAITREYA.NS's P/E ratio is 26.71. In terms of profitability, HCG.BO's ROE is +0.01%, compared to MAITREYA.NS's ROE of N/A. Regarding short-term risk, HCG.BO is less volatile compared to MAITREYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MAITREYA.NS's competition here
HCG.BO vs SANGANI.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, SANGANI.NS has a market cap of 716.4M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while SANGANI.NS trades at ₹52.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas SANGANI.NS's P/E ratio is 27.66. In terms of profitability, HCG.BO's ROE is +0.01%, compared to SANGANI.NS's ROE of N/A. Regarding short-term risk, HCG.BO is less volatile compared to SANGANI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check SANGANI.NS's competition here
HCG.BO vs AATMAJ.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, AATMAJ.NS has a market cap of 448.6M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while AATMAJ.NS trades at ₹20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas AATMAJ.NS's P/E ratio is 50.90. In terms of profitability, HCG.BO's ROE is +0.01%, compared to AATMAJ.NS's ROE of N/A. Regarding short-term risk, HCG.BO is more volatile compared to AATMAJ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check AATMAJ.NS's competition here
HCG.BO vs MEDINOV.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, MEDINOV.BO has a market cap of 433.7M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while MEDINOV.BO trades at ₹43.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas MEDINOV.BO's P/E ratio is 20.21. In terms of profitability, HCG.BO's ROE is +0.01%, compared to MEDINOV.BO's ROE of -1.80%. Regarding short-term risk, HCG.BO is less volatile compared to MEDINOV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MEDINOV.BO's competition here
HCG.BO vs NGIND.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, NGIND.BO has a market cap of 378.4M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while NGIND.BO trades at ₹116.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas NGIND.BO's P/E ratio is -27.28. In terms of profitability, HCG.BO's ROE is +0.01%, compared to NGIND.BO's ROE of -0.04%. Regarding short-term risk, HCG.BO is less volatile compared to NGIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check NGIND.BO's competition here
HCG.BO vs SML.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, SML.BO has a market cap of 311.3M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while SML.BO trades at ₹73.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas SML.BO's P/E ratio is -15.60. In terms of profitability, HCG.BO's ROE is +0.01%, compared to SML.BO's ROE of -2.04%. Regarding short-term risk, HCG.BO is less volatile compared to SML.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check SML.BO's competition here
HCG.BO vs CMMHOSP.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, CMMHOSP.BO has a market cap of 287.6M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while CMMHOSP.BO trades at ₹39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas CMMHOSP.BO's P/E ratio is -37.02. In terms of profitability, HCG.BO's ROE is +0.01%, compared to CMMHOSP.BO's ROE of +0.42%. Regarding short-term risk, HCG.BO is more volatile compared to CMMHOSP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check CMMHOSP.BO's competition here
HCG.BO vs TEJNAKSH.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, TEJNAKSH.BO has a market cap of 286.4M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while TEJNAKSH.BO trades at ₹14.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas TEJNAKSH.BO's P/E ratio is 20.74. In terms of profitability, HCG.BO's ROE is +0.01%, compared to TEJNAKSH.BO's ROE of +0.05%. Regarding short-term risk, HCG.BO is more volatile compared to TEJNAKSH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check TEJNAKSH.BO's competition here
HCG.BO vs KKSHL.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, KKSHL.BO has a market cap of 265.5M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while KKSHL.BO trades at ₹39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas KKSHL.BO's P/E ratio is -25.83. In terms of profitability, HCG.BO's ROE is +0.01%, compared to KKSHL.BO's ROE of -0.02%. Regarding short-term risk, HCG.BO is more volatile compared to KKSHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check KKSHL.BO's competition here
HCG.BO vs NIDAN.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, NIDAN.NS has a market cap of 200.9M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while NIDAN.NS trades at ₹14.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas NIDAN.NS's P/E ratio is 10.18. In terms of profitability, HCG.BO's ROE is +0.01%, compared to NIDAN.NS's ROE of N/A. Regarding short-term risk, HCG.BO is more volatile compared to NIDAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check NIDAN.NS's competition here
HCG.BO vs FAMILYCARE.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, FAMILYCARE.BO has a market cap of 169.1M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while FAMILYCARE.BO trades at ₹3.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas FAMILYCARE.BO's P/E ratio is -3.23. In terms of profitability, HCG.BO's ROE is +0.01%, compared to FAMILYCARE.BO's ROE of -0.43%. Regarding short-term risk, HCG.BO is less volatile compared to FAMILYCARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check FAMILYCARE.BO's competition here
HCG.BO vs GLHRL.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, GLHRL.BO has a market cap of 124M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while GLHRL.BO trades at ₹11.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas GLHRL.BO's P/E ratio is -5.25. In terms of profitability, HCG.BO's ROE is +0.01%, compared to GLHRL.BO's ROE of +0.01%. Regarding short-term risk, HCG.BO is more volatile compared to GLHRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check GLHRL.BO's competition here
HCG.BO vs ZDHJERK.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, ZDHJERK.BO has a market cap of 80.7M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while ZDHJERK.BO trades at ₹19.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas ZDHJERK.BO's P/E ratio is 63.55. In terms of profitability, HCG.BO's ROE is +0.01%, compared to ZDHJERK.BO's ROE of +0.01%. Regarding short-term risk, HCG.BO is more volatile compared to ZDHJERK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check ZDHJERK.BO's competition here
HCG.BO vs GIANLIFE.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, GIANLIFE.BO has a market cap of 64.2M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while GIANLIFE.BO trades at ₹6.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas GIANLIFE.BO's P/E ratio is -6.61. In terms of profitability, HCG.BO's ROE is +0.01%, compared to GIANLIFE.BO's ROE of -0.05%. Regarding short-term risk, HCG.BO is less volatile compared to GIANLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check GIANLIFE.BO's competition here
HCG.BO vs LOOKS.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, LOOKS.BO has a market cap of 61.5M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while LOOKS.BO trades at ₹6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas LOOKS.BO's P/E ratio is 29.30. In terms of profitability, HCG.BO's ROE is +0.01%, compared to LOOKS.BO's ROE of +0.01%. Regarding short-term risk, HCG.BO is more volatile compared to LOOKS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check LOOKS.BO's competition here
HCG.BO vs DLCL.BO Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, DLCL.BO has a market cap of 44.4M. Regarding current trading prices, HCG.BO is priced at ₹634.95, while DLCL.BO trades at ₹10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas DLCL.BO's P/E ratio is 13.31. In terms of profitability, HCG.BO's ROE is +0.01%, compared to DLCL.BO's ROE of +0.04%. Regarding short-term risk, HCG.BO is more volatile compared to DLCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check DLCL.BO's competition here
HCG.BO vs NEPHROCARE-ST.NS Comparison May 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 93.6B. In comparison, NEPHROCARE-ST.NS has a market cap of 0. Regarding current trading prices, HCG.BO is priced at ₹634.95, while NEPHROCARE-ST.NS trades at ₹128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 639.80, whereas NEPHROCARE-ST.NS's P/E ratio is N/A. In terms of profitability, HCG.BO's ROE is +0.01%, compared to NEPHROCARE-ST.NS's ROE of N/A. Regarding short-term risk, HCG.BO is less volatile compared to NEPHROCARE-ST.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check NEPHROCARE-ST.NS's competition here